Cancer bronchique primitif, voies de signalisation intra-cellulaires et modèles précliniques

Cancer bronchique primitif, voies de signalisation intra-cellulaires et modèles précliniques

Show other versions (1)

Contexte. Le cancer bronchopulmonaire (CBP) demeure la première cause de mortalité par cancer dans le monde. Malgré l’espoir suscité par le développement des thérapies ciblées, son pronostic demeure sombre, particulièrement dans les cas de CBP à petites cellules (CBP-PC) et de CBP non à petites cell...

Full description

Bibliographic Details
Main Author:	Mordant, Pierre
Other Authors:	Paris 11
Language:	fr
Published:	2012
Subjects:	Cancer bronchique Cancer bronchique non à petites cellules KRAS PIK3 BRAF Thérapies ciblées Modèles murins orthotopiques Cellules tumorales circulantes Lung cancer Non-small cell lung cancer Targeted therapies Orthotopic animal models Circulating tumor cells
Online Access:	http://www.theses.fr/2012PA11T092/document

Similar Items

Cancer bronchique primitif, voies de signalisation intra-cellulaires et modèles précliniques
by: Mordant, Pierre
Published: (2012)

Significance of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer patients receiving Bevacizumab: a single institution experience
by: Edita Baltruškevičienė, et al.
Published: (2016-04-01)

Identification de biomarqueurs de sensibilité et de résistance aux inhibiteurs de tyrosine kinase dans les cellules tumorales circulantes de patients atteints de cancers bronchiques non à petites cellules - Cas des remaniements ALK et ROS1
by: Pailler, Emma
Published: (2016)

Caractérisation moléculaire et fonctionnelle de cellules tumorales circulantes dans le cancer de la prostate et le cancer bronchique non à petites cellules
by: Faugeroux, Vincent
Published: (2017)

Predictive role of multiple gene alterations in response to cetuximab in metastatic colorectal cancer: A single center study
by: Ulivi Paola, et al.
Published: (2012-05-01)

Etude des mécanismes de résistances primaire et acquise aux inhibiteurs du récepteur de l’Epidermal Growth Factor dans le cancer bronchique non à petites cellules
by: Cortot, Alexis
Published: (2010)

L'empathie des soignants perçue par les patients atteints de cancer bronchique
by: Lancelot, Anne
Published: (2010)

EGFR, KRAS, BRAF, ALK, and cMET genetic alterations in 1440 Sardinian patients with lung adenocarcinoma
by: Maria Colombino, et al.
Published: (2019-11-01)

EGFR related mutational status and association to clinical outcome of third-line cetuximab-irinotecan in metastatic colorectal cancer
by: Frifeldt Sanne K, et al.
Published: (2011-03-01)

Evaluation préclinique d’une nouvelle stratégie de radiosensibilisation pharmacologique : l’inhibition des histones désacétylases
by: Rivera, Sofia
Published: (2016)

Meta-analysis of clinical trials on concordance of mutational stauts of primary tumour and distant metastases of colorectal cancer
by: M. Yu. Fedyanin, et al.
Published: (2017-04-01)

Targeting BRAF and RAS in Colorectal Cancer
by: Helene Bellio, et al.
Published: (2021-05-01)

Copy Number Amplification of the PIK3CA Gene Is Associated with Poor Prognosis in Non-lymph node metastatic Head and Neck Squamous Cell Carcinoma
by: Suda Toshihito, et al.
Published: (2012-09-01)

Caractérisation phénotypique et fonctionnelle de sous-populations Natural Killer (NK) chez des patients atteints d’un cancer bronchique non à petites cellules et impact d’une vaccination avec des exosomes de cellules dendritiques (Dex) autologues
by: Charrier, Mélinda
Published: (2016)

Analysis of EGFR, KRAS, and PIK3CA gene mutation rates and clinical distribution in patients with different types of lung cancer
by: Shuo Li, et al.
Published: (2021-07-01)

Prevalence of <it>KRAS</it>, <it>BRAF</it>, and <it>PIK3CA</it> somatic mutations in patients with colorectal carcinoma may vary in the same population: clues from Sardinia
by: Palomba Grazia, et al.
Published: (2012-08-01)

Evaluation of mutations in KRAS and BRAF genes in Iranian population with diffuse gastric cancer
by: M. Saneipour, et al.
Published: (2019-07-01)

Caractérisation et toxicité de nanoparticules manufacturées de fer chez Physcomitrella patens (Hedw. Bruch & Schimp.) et sur cellules épithéliales bronchiques humaines (HBEC) : vers une utilisation en biosurveillance d’aérocontaminants nanoparticulaires
by: Canivet, Ludivine
Published: (2013)

Molecular Genetic Studies on Prostate and Penile Cancer
by: Andersson, Patiyan
Published: (2008)

Etude des relations entre les mutations EGFR/KRAS et les altérations de la voie p53/p14arf et caractérisation d'une nouvelle cible thérapeutique, le complexe neurotensine et son récepteur1, dans les cancers bronchiques non à petites cellules
by: Younes, Mohamad
Published: (2012)

KRAS and BRAF Concomitant Mutations in a Patient with Metastatic Colon Adenocarcinoma: An Interesting Case Report
by: Concetta Cafiero, et al.
Published: (2020-06-01)

Accurate detection of KRAS, NRAS and BRAF mutations in metastatic colorectal cancers by bridged nucleic acid-clamp real-time PCR
by: Yuki Nagakubo, et al.
Published: (2019-11-01)

Comparison of the prevalence of KRAS-LCS6 polymorphism (rs61764370) within different tumour types (colorectal, breast, non-small cell lung cancer and brain tumours). A study of the Czech population
by: Magdalena Uvirova, et al.
Published: (2015-09-01)

Cancer bronchique et facteurs de risque : Existe-t-il des marqueurs phénotypiques spécifiques ?
by: Clément-Duchene, Christelle
Published: (2009)

Alterations in epidermal growth factor receptors 1 and 2 in esophageal squamous cell carcinomas
by: Gonzaga Isabela Martins, et al.
Published: (2012-12-01)

Comparison of KRAS and PIK3CA gene status between primary tumors and paired metastases in colorectal cancer
by: He Q, et al.
Published: (2016-04-01)

Mutational profiles of marker genes of cervical carcinoma in Bangladeshi patients
by: Shahana Sharmin, et al.
Published: (2021-03-01)

KRAS and BRAF mutations in Iranian colorectal cancer patients: A systematic review and meta-analysis
by: Abolfazl Yari, et al.
Published: (2020-06-01)

The prognostic significance of KRAS and BRAF mutation status in Korean colorectal cancer patients
by: Daeyoun David Won, et al.
Published: (2017-06-01)

Crosstalk Between DNA Methylation and Gene Mutations in Colorectal Cancer
by: Maria Dobre, et al.
Published: (2021-07-01)

Biomarqueurs cellulaires circulants dans les cancers avancés
by: Massard, Christophe
Published: (2013)

Combined inhibition of MEK and Aurora A kinase in KRAS/PIK3CA double-mutant colorectal cancer models
by: S. Lindsey eDavis, et al.
Published: (2015-06-01)

Detection of mutations in circulating cell‐free DNA in relation to disease stage in colorectal cancer
by: Sandra Liebs, et al.
Published: (2019-07-01)

Prevalence of RAS and BRAF mutations in metastatic colorectal cancer patients by tumor sidedness: A systematic review and meta‐analysis
by: Lauren C. Bylsma, et al.
Published: (2020-02-01)

Cross-species analysis of genetically engineered mouse models of MAPK-driven colorectal cancer identifies hallmarks of the human disease
by: Peter J. Belmont, et al.
Published: (2014-06-01)

Conséquences de la dérégulation de MET sur le phénotype des cancers bronchiques non à petites cellules EGFR mutés devenus résistant aux inhibiteurs de tyrosine kinase d’EGFR
by: Baldacci, Simon
Published: (2017)

Evaluation of EGFR, KRAS and BRAF gene mutations in renal cell carcinoma
by: Omer Bayrak, et al.
Published: (2014-08-01)

Coexistence of KRAS and BRAF Mutations in Colorectal Cancer: A case report supporting the concept of tumoral heterogeneity
by: Pegah Larki, et al.
Published: (2017-05-01)

Expression du facteur tissulaire dans le cancer bronchique non à petites cellules : relation avec l'angiogenèse tumorale et les mutations des gènes K-RAS, p53, PTEN ET LKB1.
by: Regina, Sandra
Published: (2008)

Beyond KRAS: Practical Molecular Targets in Pancreatic Adenocarcinoma
by: Albert Grinshpun, et al.
Published: (2019-01-01)